Sapient Partners with Alamar Biosciences for Enhanced Proteomics
Sapient, a leader in the field of multi-omics discovery, is proud to announce a new partnership with Alamar Biosciences. This collaboration aims to expand Sapient's proteomics services, specifically in the realm of cytokine, chemokine, and neuroinflammatory mediator assays. Alamar, known for its advanced immunoassay technologies, has developed the innovative NULISA™ platform, which will be integral to this new offering.
Utilizing NULISA™ and ARGO® HT Technologies
As part of this partnership, Sapient will utilize the NULISAseq™ platform, which encompasses both multiplex and single-plex assays. This technology is capable of profiling over 250 cytokine and chemokine biomarkers. Furthermore, it includes the CNS Disease Panel, enabling the assessment of more than 120 low-abundance neurodegeneration and neuroinflammatory biomarkers, custom-designed for precision proteomics applications.
Improving Sensitivity in Protein Detection
The NULISA technology employs a sophisticated approach that significantly enhances the sensitivity of traditional assays, making it possible to detect low-abundance proteins in challenging biofluid samples. This capability is a game-changer for researchers and developers seeking to uncover novel biomarkers and validate drug targets with precision.
Complementing Existing Multi-Omics Solutions
Sapient's partnership with Alamar strengthens their existing mass spectrometry-based proteomics efforts. This integration allows for a comprehensive examination of the proteome, enlisting NULISA for the validation of critical proteins discovered through mass spectrometry. Collectively, these multi-omic strategies cover a broader spectrum of dynamic biomarkers related to health and disease.
Insights from Leadership
Jonathan Usuka, the CEO of Sapient, expressed enthusiasm about the collaboration, stating, "The addition of NULISA-based profiling will enable our clients to gain deeper insights into human health and disease by accurately capturing subtle changes in biomarker dynamics." This sentiment was echoed by Yuling Luo, CEO of Alamar, who emphasized the importance of high-sensitivity technologies for early disease detection and therapeutic development.
About Sapient
Sapient is at the cutting edge of biomarker discovery, utilizing high-throughput mass spectrometry along with sophisticated biocomputational techniques to provide superior data analysis. Their Human Biology Database, which contains extensive data from over 100,000 samples, facilitates rapid identification of drug targets and supports all phases of drug development. For more information about Sapient’s innovative approach, visit sapient.bio.
About Alamar Biosciences, Inc.
Alamar Biosciences is dedicated to advancing the field of precision proteomics. Their robust NULISA Platform, coupled with the ARGO® HT System, prides itself on achieving unmatched sensitivity in protein detection far surpassing conventional methods. For deeper insights into their groundbreaking work, check alamarbio.com.
Frequently Asked Questions
1. What is the purpose of the partnership between Sapient and Alamar Biosciences?
The collaboration aims to enhance targeted proteomics services by offering high-sensitivity cytokine, chemokine, and neuroinflammatory assays utilizing Alamar's NULISA platform.
2. What technologies are being implemented in this partnership?
Sapient will use the NULISAseq™ platform and the ARGO® HT System to perform a range of multiplex and single-plex assays for biomarker discovery.
3. How does NULISA technology improve protein detection?
NULISA significantly enhances the sensitivity of traditional assays, permitting the detection of proteins at attomolar levels, which is crucial for measuring low-abundance biomarkers.
4. Why are cytokines and chemokines important in research?
Cytokines and chemokines are vital modulators of immune responses and serve as significant indicators of various diseases, making their study essential for developing targeted therapies.
5. How does this partnership benefit drug development?
By integrating NULISA with mass spectrometry, the partnership supports comprehensive biomarker validation and discovery, advancing the drug development pipeline from research to clinical trials.
